Clinical Trials Logo

Acute Migraine clinical trials

View clinical trials related to Acute Migraine.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05371652 Completed - Acute Migraine Clinical Trials

A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants

Start date: May 19, 2022
Phase: Phase 3
Study type: Interventional

This trial is to evaluate the long-term safety and tolerability of Rimegepant 75mg ODT in Chinese subjects with migraine

NCT ID: NCT04574362 Completed - Acute Migraine Clinical Trials

Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine

Start date: October 22, 2020
Phase: Phase 3
Study type: Interventional

This trial is to determine whether BHV3000 (rimegepant) 75mg is safe and effictive as a treatment for acute migraine in Chinese and Korean patients

NCT ID: NCT04408794 Completed - Acute Migraine Clinical Trials

Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

Start date: June 29, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine. * BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN ) Council for use in the U.S. and is pending formal adoption by the INN for international use.

NCT ID: NCT04218162 Completed - Acute Migraine Clinical Trials

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean

Start date: March 24, 2020
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and safety of lasmiditan tablet compared to Placebo in the acute treatment of Migraine

NCT ID: NCT04153409 Completed - Acute Migraine Clinical Trials

A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine

Start date: September 24, 2019
Phase: Phase 2
Study type: Interventional

This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.

NCT ID: NCT03631550 Completed - Acute Migraine Clinical Trials

The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine

Start date: November 29, 2018
Phase: N/A
Study type: Interventional

this study will evaluate the clinical performance and safety of a self administered abortive treatment for migraine headache using combined occipital and supraorbital transcutaneous nerve stimulator (Neurolief device, Relivion®)

NCT ID: NCT02745392 Completed - Acute Migraine Clinical Trials

Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

Zotrip
Start date: June 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.

NCT ID: NCT02684409 Completed - Acute Migraine Clinical Trials

Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine

Start date: August 2013
Phase: Phase 1
Study type: Interventional

This will be a Phase 1, multiple center, open label, single-dose study in otherwise healthy adolescent subjects with a history of acute migraine. Subjects will each receive one Zecuity patch application. Subjects will be admitted 2 hours prior to dosing on Day 1, and will remain in the clinical unit under supervision until the last pharmacokinetic (PK) sample is obtained. Blood will be obtained at prescribed times for PK analysis and safety assessments will be performed, including adverse event monitoring, 12-lead ECG test, patch adhesion evaluations, skin irritation evaluations, and vital signs.

NCT ID: NCT02439320 Completed - Acute Migraine Clinical Trials

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:

SAMURAI
Start date: April 2015
Phase: Phase 3
Study type: Interventional

This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).

NCT ID: NCT02279082 Completed - Acute Migraine Clinical Trials

DFN-02 Open Label Safety Study in Patients With Acute Migraine

Start date: September 2014
Phase: Phase 3
Study type: Interventional

A multi-center, open-label, safety study of DFN-02 for the Treatment of Acute Migraines